Monday, October 26, 2026 · Daily editionET --:--:--

Finished

Randomized Evaluation of Patients Who Have Had Laparoscopic Partial Nephrectomy

NCT04120805 · University of Chicago · Updated 21 Oct 2026

What is being tested
Hemostatic Agent; No Hemostatic Agent
For
Kidney Cancer
Kind of study
Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
Who can join
Ages 18 years and older. About 208 people. The full rules are on the registry page.
Where
United States
When
Starts or started 1 Jan 2016, ends 18 Nov 2025. Registered 9 Oct 2019.
Results
Posted on the registry on 21 Oct 2026.

In the researchers' words

The purpose of this study is to evaluate the necessity of using hemostatic agents as a tool when performing robotic partial nephrectomy in the treatment of kidney cancer. This project asks whether patients who undergo robotic partial nephrectomy without the surgeon using hemostatic agents during the procedure will have the same, fewer, or more complications than when patients undergo this same surgery with the surgeon using hemostatic agents during the procedure.
ClinicalTrials.gov, NCT04120805

Sites

  • The University of ChicagoChicago, Illinois, United States